Offshore Public Offerings

• Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) in its approximately US$43 million IPO and listing on the Hong Kong Stock Exchange
• TYK Medicines (2410.HK) in its approximately US$74 million IPO and listing on the Hong Kong Stock Exchange
• CICC as sole sponsor and 20 other underwriters in approximately US$85 million IPO of Shanghai Voicecomm Information Technology Co., Ltd. (2495.HK) on the Hong Kong Stock Exchange
• Ruichang International Holdings Limited (1334.HK) in its approximately US$17 million IPO and listing on the Hong Kong Stock Exchange
• Laopu Gold (6181.HK) in its approximately US$116 million IPO and listing on the Hong Kong Stock Exchange
• Qunabox Group (0917.HK) in its approximately US$63 million IPO and listing on the Hong Kong Stock Exchange
• Sunho Biologics (2898.HK) in Approximately US$60 Million IPO and listing on the Hong Kong Stock Exchange
• CICC as the sole sponsor and overall coordinator in the approximately US$31 million IPO of Qyuns Therapeutics Co., Ltd. (2509.HK) on the Hong Kong Stock Exchange
• Folangsi Co., Ltd (2499.HK) in its HK$155 million (approximately US$20.15 million) IPO and listing on the Hong Kong Stock Exchange
• Beijing UBOX Online Technology Corp. (2429.HK) in its approximately US$30 million IPO and listing on the Hong Kong Stock Exchange, marking the first Hong Kong listing of a company in the unmanned retail industry
• Tiantu Capital (1973.HK) in its approximately US$144 million IPO and listing on the Hong Kong Stock Exchange, marking the first-ever listing of a PRC VC firm in Hong Kong
• Adlai Nortye Ltd. (NASDAQ: ANL) in its approximately US$100 million IPO on the Nasdaq
• CICC, CCB, CMB, CMS and other underwriters in the approximately US$150 million IPO of Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) on the Hong Kong Stock Exchange
• Beijing Luzhu Biotechnology Co., Ltd. in its US$43 million IPO and listing on the Hong Kong Stock Exchange
• Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
• Cryofocus Medtech (Shanghai) Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• 3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
• Gaush Meditech Ltd. in its US$86 million IPO and listing on the Hong Kong Stock Exchange
• Jenscare Scientific Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• ABCI Captial Limited, CICC Hong Kong Securities Limited and other underwriters in the H-share IPO of Lushang Life Services Co., Ltd (2376.HK) on the Hong Kong Stock Exchange
• Rainmed Medical Limited in its IPO and listing on the Hong Kong Stock Exchange
• Shanghai Bio-heart Biological Technology Co., Ltd. in its US$65.3 million IPO and listing on the Hong Kong Stock Exchange
• Yonghe Medical Group Co., Ltd. in its US$206 million IPO and listing on the Hong Kong Stock Exchange
• Gushengtang Holdings Limited in its US$104 million IPO and listing on the Hong Kong Stock Exchange
• Acotec Scientific Holdings Limited in its US$210 million IPO and listing on the Hong Kong Stock Exchange
• Goldman Sachs (Asia) L.L.C. and CICC and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
• Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
• Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
• JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange
• J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
• Simcere Pharmaceutical Group Limited in its US$461 million IPO and listing on the Hong Kong Stock Exchange
• Honliv Healthcare Management Group Company Limited in its US$41.3 million IPO and listing on the Hong Kong Stock Exchange
• Hygeia Healthcare Holdings Co., Limited in its US$286 million IPO and listing on the Hong Kong Stock Exchange
• Yeahka Limited in its US$212 million IPO and listing on the Hong Kong Stock Exchange
• Peijia Medical Limited in its US$343 million IPO and listing on the Hong Kong Stock Exchange
• Akeso Biopharma in its US$383 million IPO and listing on the Hong Kong Stock Exchange
• Guotai Junan Capital as sole sponsor and Guotai Junan Securities (Hong Kong) as main underwriter, and other underwriters in the US$65 million IPO and listing of Zhongguancun Science-Tech Leasing on the Hong Kong Stock Exchange
• First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US$71 Million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
• Shanghai Kindly Medical Instrument Co., Ltd., in its US$106 million IPO and listing on the Hong Kong Stock Exchange
• Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
• Aesthetic Medical International Holdings in its US$34.5 million IPO on the Nasdaq
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
• Viva Biotech (1873.HK) in its HK$1,521.5 million (approximately US$194 million) IPO and listing on the Hong Kong Stock Exchange
• Bank of Qingdao (03866.HK) in its US$531 million IPO and listing on the Hong Kong Stock Exchange
• Holly Futures Co., Ltd., a leading China-based futures company, in its US$63 million IPO of H-shares on the Main Board of the Hong Kong Stock Exchange
• UBS as sole global coordinators, bookrunner, lead manager and sponsor in the US$106 million IPO of China Huirong Financial Holdings Ltd. on the Main Board of the Hong Kong Stock Exchange
• Morgan Stanley and CCBI as joint sponsors and joint global coordinators in the US$250 million IPO of Harmonicare Medical Holdings Limited on the Main Board of the Hong Kong Stock Exchange
• Chanjet Information Technology Company Limited in the US$116 million IPO of its H-shares on the Main Board of the Hong Kong Stock Exchange. This was the first spin-off listing of an A-share listed company on the Hong Kong Stock Exchange
• China Vanke Co., Ltd. in the conversion of US$2.1 billion B-shares into H-shares and the listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction
• Guosen Securities (HK) Capital Company Limited as sole sponsor in the conversion of Livzon Pharmaceutical Group Inc.’s US$548 million B-shares into H-shares and listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction
• China International Marine Containers (Group) Co., Ltd. in the conversion of US$1.8 billion B-shares into H-shares and listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction. This was the first B-to-H listing on the Hong Kong Stock Exchange
• CITIC Securities, UBS, and Bank of America Merrill Lynch as joint global coordinators and other underwriters in the US$319 million IPO of the H-shares of Huadian Fuxin Energy Corporation on the Main Board of the Hong Kong Stock Exchange
• Haitong Securities Co. Ltd. in the US$1.68 billion IPO of its H-shares on the Main Board of the Hong Kong Stock Exchange
• Morgan Stanley, Citigroup, and Credit Suisse as joint global coordinators and other syndicate of banks in the US$12 billion global offering and dual listing of Glencore International in both London and Hong Kong
• CICC and Morgan Stanley as joint sponsors in the listing of Guangzhou Auto by way of introduction through privatization of a HK-listed auto company on the Main Board of the Hong Kong Stock Exchange
• Microport Scientific Corporation in its US$200 million IPO on the Main Board of the Hong Kong Stock Exchange 

Mergers and Acquisitions

• Acotec Scientific in its approximately US$520 million voluntary partial offer by Boston Scientific
• Viva Biotech in its US$387.3 million acquisition of Langhua Pharmaceutical and US$135.4 million share placement
• Nat-Ace Pharmaceutical in its US$35 million acquisition of approximately 52.79% equity interest in the HK-listed Perception Digital Holdings Limited from its then controlling shareholders by way of an unconditional, mandatory cash offer to acquire all the issued shares and cancel all outstanding options
• Geely Automobile in its acquisition of Volvo Group from Ford Group at US$1.8 billion
• Newbridge Capital in its sale of approximately 16.67% equity interest in Shenzhen Development Bank to Ping An Insurance at US$1.68 billion
• China International Marine Containers (CIMC), in connection with its wholly owned subsidiary CIMC Hong Kong, in its sale of 70% equity interest in CIMC-TianDa to Pteris Global Limited (Pteris). As consideration, Pteris would issue US$75 million new shares to CIMC Hong Kong for its reverse takeover and become a subsidiary of CIMC. This transaction was deemed a new listing of Pteris on the Singapore Exchange
• Tenwow International in its pre-IPO investments in several rounds of bidding and accepting offers from various pre-IPO investors immediately before its US$203 million IPO on the Main Board of the Hong Kong Stock Exchange